CardioGenics Holdings (CardioGenics Holdings) EBIT : $-0.77 Mil (TTM As of Jan. 2016)

View and export this data going back to 2004. Start your Free Trial

What is CardioGenics Holdings EBIT?

CardioGenics Holdings's earnings before interest and taxes (EBIT) for the three months ended in Jan. 2016 was $-0.20 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jan. 2016 was $-0.77 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. CardioGenics Holdings's annualized ROC % for the quarter that ended in Jan. 2016 was -75.32%. CardioGenics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2016 was -2,330.43%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

CardioGenics Holdings EBIT Historical Data

The historical data trend for CardioGenics Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CardioGenics Holdings EBIT Chart

CardioGenics Holdings Annual Data

Trend

Jul06

Jul07

Jul08

Oct09

Oct10

Oct11

Oct12

Oct13

Oct14

Oct15

EBIT

Get a 7-Day Free Trial

-5.60

-1.30

-2.33

-0.97

-0.77

CardioGenics Holdings Quarterly Data
	Apr11	Jul11	Oct11	Jan12	Apr12	Jul12	Oct12	Jan13	Apr13	Jul13	Oct13	Jan14	Apr14	Jul14	Oct14	Jan15	Apr15	Jul15	Oct15	Jan16
EBIT	Get a 7-Day Free Trial															-0.21	-0.16	-0.10	-0.31	-0.20

Competitive Comparison of CardioGenics Holdings's EBIT

For the Diagnostics & Research subindustry, CardioGenics Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CardioGenics Holdings's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CardioGenics Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CardioGenics Holdings's EV-to-EBIT falls into.

CardioGenics Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jan. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.77 Mil.

CardioGenics Holdings (OTCPK:CGNH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

CardioGenics Holdings's annualized ROC % for the quarter that ended in Jan. 2016 is calculated as:

	ROC % (Q: Jan. 2016 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Oct. 2015 )	+	Invested Capital (Q: Jan. 2016 ))	/ count )
=	-0.804 * ( 1 - 0% )	/	( (1.084	+	1.051)	/ 2 )
=	-0.804	/	1.0675
=	-75.32 %

where

	Invested Capital		(Q: Oct. 2015 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.232	-	0.891	-	( 0.05	-	max(0, 1.795	-	0.052	+	0.05	))
=	1.084

	Invested Capital		(Q: Jan. 2016 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.558	-	1.467	-	( 0	-	max(0, 2.345	-	0.385	+	0	))
=	1.051

Note: The Operating Income data used here is four times the quarterly (Jan. 2016) data.

2. Joel Greenblatt's definition of Return on Capital:

CardioGenics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2016 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jan. 2016 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Oct. 2015		Q: Jan. 2016
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.804	/	( ( (0.035 + max(-1.722, 0))	+	(0.034 + max(-1.587, 0)) )	/	2 )
=	-0.804	/	( ( 0.035	+	0.034 )	/	2 )
=	-0.804	/	0.0345
=	-2,330.43 %

where Working Capital is:

	Working Capital		(Q: Oct. 2015 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	-6.9388939039072E-18)	-	(0.891	+	0.487	+	0.344)
=	-1.722

	Working Capital		(Q: Jan. 2016 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.38	+	0	+	0)	-	(1.467	+	0	+	0.5)
=	-1.587

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2016) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

CardioGenics Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jan. 2016 )
	=	-0.768	/	0.000
	=	%

CardioGenics Holdings EBIT Related Terms

Thank you for viewing the detailed overview of CardioGenics Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

CardioGenics Holdings (CardioGenics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CardioGenics Holdings Inc (OTCPK:CGNH) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

6295 Northam Drive, Unit 8, Mississauga, ON, CAN, L4V 1W8

Website

http://www.cardiogenics.com

CardioGenics Holdings Inc is a biotechnology company. It is engaged in the development and commercialization of diagnostic test products for the In-Vitro Diagnostics (IVD) testing market. The company's objective is to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies. Its products include QL Care Analyzer, Immunoassay Tests, and Paramagnetic Beads. The business activity is primarily carried out through the region of Canada.

CardioGenics Holdings (CardioGenics Holdings) Headlines

No Headlines